Avtal | $24,000,000 | (Mar 20, 2026)
Parallel(FRANCE) | $20,000,000 | (Mar 20, 2026)
Claros | $30,000,000 | (Mar 20, 2026)
Certified by Founder
Lodge
Arpeggio Biosciences
start up
United States
- Boulder, CO
- 08/09/2022
- Series A
- $17,000,000
Our technology combines a proprietary biological assay and machine learning algorithms that, together, enable rapid, high-resolution snapshots of cellular dynamics following drug treatment. These snapshots are then analyzed to reveal the biological networks that determine a drug’s function and guide therapeutic development.
We are comprised of a talented, diversely-skilled team, working together towards the mission of helping bring new therapies to patients with epigenetically-driven diseases.
- Industry Biotechnology Research
- Website https://www.arpeggiobio.com/
- LinkedIn https://www.linkedin.com/company/arpeggio-biosciences/
Related People
Joey AzofeifaFounder
United States -
Boulder, Colorado
I work with biologists, mathematicians and computer scientists to build technology that will better our understanding of human disease.
Latent | $80,000,000 | (Mar 20, 2026)
Corridor | $25,000,000 | (Mar 20, 2026)
RunSybil | $40,000,000 | (Mar 20, 2026)
PADO AI | $6,000,000 | (Mar 20, 2026)
Edra | $30,000,000 | (Mar 20, 2026)
Chalkie AI | $4,000,000 | (Mar 20, 2026)
Deeptune | $43,000,000 | (Mar 20, 2026)
SetSale | $2,000,000 | (Mar 19, 2026)
Laminar (YC S24) | $3,000,000 | (Mar 19, 2026)